Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis.

@article{Jazirehi2005RituximabA,
  title={Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-\{kappa\}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis.},
  author={Ali R. Jazirehi and Sara Huerta-Y{\'e}pez and Genhong Cheng and Benjamin Bonavida},
  journal={Cancer research},
  year={2005},
  volume={65 1},
  pages={264-76}
}
The chimeric anti-CD20 antibody rituximab (Rituxan, IDEC-C2B8) is widely used in the clinical treatment of patients with non-Hodgkin's lymphoma (NHL). Rituximab sensitizes NHL B-cell lines to drug-induced apoptosis via down-regulation of Bcl-x(L) expression. We hypothesized that the mechanism by which rituximab down-regulates Bcl-x(L) may be, in part, due to inhibition of constitutive nuclear factor-kappaB (NF-kappaB) activity that regulates Bcl-x(L) expression. This hypothesis was tested in… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 97 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 58 references

NF-kappaB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes.

Proceedings of the National Academy of Sciences of the United States of America • 1999
View 5 Excerpts
Highly Influenced

Raf kinase inhibitor (RKIP): structure, function, regulation of cell signaling and apoptosis

G Odabaie, D Chatterjee, +3 authors B. Bonavida
Adv Cancer Res • 2004

Similar Papers

Loading similar papers…